238 related articles for article (PubMed ID: 9621033)
1. B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.
Lovmand J; Sorensen AB; Schmidt J; Ostergaard M; Luz A; Pedersen FS
J Virol; 1998 Jul; 72(7):5745-56. PubMed ID: 9621033
[TBL] [Abstract][Full Text] [Related]
2. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.
Amtoft HW; Sørensen AB; Bareil C; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Jul; 71(7):5080-7. PubMed ID: 9188573
[TBL] [Abstract][Full Text] [Related]
3. Enhancer mutations of Akv murine leukemia virus inhibit the induction of mature B-cell lymphomas and shift disease specificity towards the more differentiated plasma cell stage.
Sørensen KD; Kunder S; Quintanilla-Martinez L; Sørensen J; Schmidt J; Pedersen FS
Virology; 2007 May; 362(1):179-91. PubMed ID: 17258785
[TBL] [Abstract][Full Text] [Related]
4. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
Ethelberg S; Lovmand J; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
[TBL] [Abstract][Full Text] [Related]
5. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
Sørensen KD; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
[TBL] [Abstract][Full Text] [Related]
6. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.
Ethelberg S; Hallberg B; Lovmand J; Schmidt J; Luz A; Grundström T; Pedersen FS
J Virol; 1997 Feb; 71(2):1196-206. PubMed ID: 8995642
[TBL] [Abstract][Full Text] [Related]
7. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.
Nieves A; Levy LS; Lenz J
J Virol; 1997 Feb; 71(2):1213-9. PubMed ID: 8995644
[TBL] [Abstract][Full Text] [Related]
8. Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus.
Starkey CR; Lobelle-Rich PA; Granger SW; Brightman BK; Fan H; Levy LS
J Virol; 1998 Feb; 72(2):1078-84. PubMed ID: 9445002
[TBL] [Abstract][Full Text] [Related]
9. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.
Morrison HL; Soni B; Lenz J
J Virol; 1995 Jan; 69(1):446-55. PubMed ID: 7983741
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles of enhancer nuclear factor 1 (NF1) sites in plasmacytoma and osteopetrosis induction by Akv1-99 murine leukemia virus.
Sørensen KD; Sørensen AB; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
Virology; 2005 Apr; 334(2):234-44. PubMed ID: 15780873
[TBL] [Abstract][Full Text] [Related]
11. The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity.
Pantginis J; Beaty RM; Levy LS; Lenz J
J Virol; 1997 Dec; 71(12):9786-91. PubMed ID: 9371646
[TBL] [Abstract][Full Text] [Related]
12. Non-identical patterns of proviral insertions around host transcription units in lymphomas induced by different strains of murine leukemia virus.
Martín-Hernández J; Balle Sørensen A; Pedersen FS
Virology; 2006 Sep; 353(1):193-9. PubMed ID: 16790256
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.
Zaiman AL; Lewis AF; Crute BE; Speck NA; Lenz J
J Virol; 1995 May; 69(5):2898-906. PubMed ID: 7707514
[TBL] [Abstract][Full Text] [Related]
14. Ecotropic and mink cell focus-forming murine leukemia viruses integrate in mouse T, B, and non-T/non-B cell lymphoma DNA.
Zijlstra M; Quint W; Cuypers T; Radaszkiewicz T; Schoenmakers H; de Goede R; Melief C
J Virol; 1986 Mar; 57(3):1037-47. PubMed ID: 3005610
[TBL] [Abstract][Full Text] [Related]
15. Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.
Nielsen AA; Sørensen AB; Schmidt J; Pedersen FS
J Virol; 2005 Jan; 79(1):67-78. PubMed ID: 15596802
[TBL] [Abstract][Full Text] [Related]
16. Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.
Boral AL; Okenquist SA; Lenz J
J Virol; 1989 Jan; 63(1):76-84. PubMed ID: 2535754
[TBL] [Abstract][Full Text] [Related]
17. Addition of substitution of simian virus 40 enhancer sequences into the Moloney murine leukemia virus (M-MuLV) long terminal repeat yields infectious M-MuLV with altered biological properties.
Hanecak R; Pattengale PK; Fan H
J Virol; 1988 Jul; 62(7):2427-36. PubMed ID: 2836623
[TBL] [Abstract][Full Text] [Related]
18. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
Martiney MJ; Rulli K; Beaty R; Levy LS; Lenz J
J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
[TBL] [Abstract][Full Text] [Related]
19. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
Ethelberg S; Tzschaschel BD; Luz A; Diaz-Cano SJ; Pedersen FS; Schmidt J
J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
[TBL] [Abstract][Full Text] [Related]
20. Differential DNA binding of nuclear proteins to a long terminal repeat region of the MCF13 and Akv murine leukemia viruses.
Yoshimura FK; Tupper J; Diem K
J Virol; 1989 Nov; 63(11):4945-8. PubMed ID: 2552174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
